



Corporate Presentation | August 2020

Forward-Looking Statements


This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forwardlooking statements contain these identifying words. Clearside Biomedical, Inc.'s views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause Clearside's actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although Clearside believes that the expectations reflected in the forward-looking statements are reasonable, Clearside cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from Clearside's expectations include its plans to develop and potentially commercialize its product candidates; Clearside's planned clinical trials and preclinical studies for its product candidates; the timing of and Clearside's ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Clearside's product candidates; the clinical utility and market acceptance of Clearside's product candidates; Clearside's commercialization, marketing and manufacturing capabilities and strategy; Clearside's intellectual property position; and Clearside's ability to identify additional product candidates with significant commercial potential that are consistent with its commercial objectives. For further information regarding these risks, uncertainties and other factors you should read the "Risk Factors" section of Clearside's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 13, 2020, Clearside's Quarterly Report on Form 10-Q for the guarter ended June 30, 2020, filed with the SEC on August 10, 2020, and Clearside's other Periodic Reports filed with the SEC. Clearside expressly disclaims any obligation to update or revise the information herein, including the forwardlooking statements, except as required by law. This presentation also contains estimates and other statistical data made by independent parties and by Clearside relating to market size and growth and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of Clearside's future performance and the future performance of the markets in which Clearside operates are necessarily subject to a high degree of uncertainty and risk.



Developing and Delivering Treatments that Restore and Preserve Vision for People with Serious Back of the Eye Diseases

Versatile Therapeutic Platform

SCS Microinjector[®] with proprietary drug formulations target the Suprachoroidal Space



Proprietary Access to the Suprachoroidal Space (SCS[®])

Utilization Across Small Molecules and Gene Therapy

Ability to Target Multiple Ocular Diseases

Internal Research & Development Pipeline

External Collaborations for Pipeline Expansion



Evolution of Injection Procedures to Reach the Back of the Eye




Periocular Injection

Highly variable drug diffusion across the sclera into the eye



Intravitreal Injection


Broad diffusion to all areas of the eye including the anterior chamber and lens



Subretinal Injection

Invasive surgery with variable results


Suprachoroidal Space Injection



Novel SCS Microinjector[®] allows for precise delivery into the suprachoroidal space



Exclusive Access to the Back of the Eye Using Clearside's Proprietary SCS Microinjector®






Core Advantages of Treating Via the Suprachoroidal Space



...........





TARGETED

6

COMPARTMENTALIZED

The back of the eye is the location of many irreversible and debilitating visual impairments Drug is compartmentalized in the suprachoroidal space, which helps keep it away from non-diseased tissues

for efficacy

for safety

BIOAVAILABLE PROLONGED PK


Fluid spreads circumferentially and posteriorly when injected within the suprachoroidal space, bathing the choroid and adjacent areas with drug

for durability



PK = pharmacokinetic | Sources: Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. | Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal space: from potential space to a space with potential. Clin Ophthalmol. 2016;10:173-178. | Chiang B, Jung JH, Prausnitz MR. The suprachoroidal space as a route of administration to the posterior segment of the eye. Adv Drug Deliv Rev. 2018;126:58-66.

Strong Intellectual Property Coverage of SCS Platform





Suprachoroidal Internal Development Pipeline

STUDY DRUG	INDICATION	RESEARCH	PRECLINICAL	PHASE 1/2	PHASE 3	NDA
CLS-AX (axitinib injectable suspension)	Wet AMD			Planned YE 20		
Gene Therapy: Intracellular protein	Inherited Retinal Disease					
Gene Therapy: Extracellular protein	"Therapeutic Biofactory"					
Integrin Inhibitor (Injectable suspension)	Diabetic Macular Edema (DME)					



Partnered Suprachoroidal Pipeline

Development and Commercial Programs using SCS Microinjector®

PARTNER	INDICATION	IND-Enabling	PHASE 2	PHASE 3	NDA
REGENXBIO	Wet AMD (AAVIATE)				
REGENXBIO	Diabetic Retinopathy		Planned 2H 20		
AURA BIOSCIENCES	Ocular Oncology / Choroidal Melanoma		Planned 3Q 20		

XIPERE™ Commercial Licenses

PARTNER	TERRITORY	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	NDA
BAUSCH HEALTH	U.S. & Canada; options outside North America					
ARCTIC VISION	Greater China & South Korea					



CLS-AX (axitinib injectable suspension)



CLS-AX (axitinib injectable suspension): A Potential Solution for Treatment Burden

Primary Need Durable maintenance of vision and reduced treatment burden in wet AMD patients

The Opportunity

- Reduce patient burden from monthly injections to every six months or longer
- Pan-VEGF inhibition potentially more efficacious than current approaches
- Improve long-term, real-world visual outcomes for patients
- Provide physicians with ability to titrate dose based on patient need
- Protect the anterior chamber from toxic exposure to TKIs



CLS-AX via SCS May Address Unmet Needs in wet AMD

TREATMENT BURDEN	At 1 year, "real-world" patients receive only 6-7 injections ^{4,5}	Under-treatment contributes to poor real-world outcomes
LIMITED OUTCOMES	At 1 year, with on-label anti-VEGF dosing ¹⁻³ : ~1/5 of patients lose BCVA	At 1 year, "real-world" patients improve by
	~1/2 do not achieve ≥ 20/40 ~2/3 do not gain ≥ 3 lines BCVA	only 1-3 letters ^{4,5}
CEILING OF EFFICACY	Increased anti-VEGF dosage or more intense regimens yield no additional BCVA benefit ^{1,6,7}	


Sources: 1. Heier JS et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-2548. | 2. Brown DM et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.e5. | 3. Rosenfeld PJ et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431. | 4. Ciulla TA et al. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49,485 Eyes. Ophthalmology. 2019;125:5226528. | 5. Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry. Ophthalmology. 2018;125:5226528. | 6. Busbee BG et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046-1056. | 7. Schmidt-Erfurth U et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193-201.



AMD Vascular Endothelial Growth Factor Treatment Approaches

Current AMD Therapies Predominantly Focus on Binding VEGF-A

- Anti-VEGF-A increases expression of VEGF-C¹VEGF-D²
- Broad VEGF receptor blockade may improve outcomes
- A Phase 2 study yielded better AMD outcomes with anti-VEGF-A,C,D vs anti-VEGF-A



Suprachoroidal Axitinib May Improve Outcomes with Its Broad VEGF Receptor Blockade


- Inhibits VEGFR-1, VEGFR-2, VEGFR-3 receptors
- Inhibited corneal, retinal, and choroidal angiogenesis in animal models³⁻⁷
- More effective than other TKIs for experimental corneal neovascularization in animal models
- Better ocular cell biocompatibility than other TKIs⁸

Sources: 1. Cabral T et al. Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers. Ophthalmol Retina. 2018 January ; 2(1): 31–37. doi:10.1016/j.oret.2017.04.004. | 2. Lieu et al. The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer. PLoS ONE 8(10): e77117. | 3. Riquelme et al. Topical axitinib is a potent inhibitor of corneal neovascularization. Clinical and Experimental Ophthalmology 2018; 46: 1063–1074 | 4. Yuan et al. Ocular Drug Delivery Nanowafer with Enhanced Therapeutic Efficacy. ACS Nano. 2015 Feb 24;9(2):1749-58. | 5. Giddabasappa et al. Axitinib inhibits retinal and choroidal neovascularization in in-vitro and in-vitro an



13

Topical Axitinib More Effectively Inhibited Experimental Murine Corneal Neovascularization than Sunitinib and Sorafenib (same dose)




Screening of tyrosine kinase inhibitor drugs loaded nanowafers for their relative therapeutic efficacy in inhibiting corneal neovascularization after 10 days of treatment. Representative 3D reconstructed corneal images of fluorescence confocal microscopy: (a) healthy cornea (control); (b) untreated ocular burn (control); (c) blank PVA-NW; (d) Sora-NW; (e) Suni-NW; (f) Axi-NW. (g) Quantification of corneal neovascularization volume. n=3 animals, *P<0.05 vs OB control and P<0.05 vs PVA-NW, **P<0.01. All error bars represent standard deviation from the mean.



Potential to Disrupt the AMD Treatment Landscape


Focused VEGF Blockade

Broad VEGF Blockade






Suprachoroidal Injection of CLS-AX Provides Targeted Delivery Relative to Intravitreal Injection at Same Dose



CLS-AX: <u>Durable</u>, High Drug Levels Maintained in the Retina after **Suprachoroidal Administration**



SCS : 1 mg/eye, 100 μL. | IVT: 1 mg/eye, 25 μL Single bilateral injection, 1-wk rabbit PK studies

Time (days)



Source: Based on Clearside Biomedical preclinical data

Abbreviations: SCS: Suprachoroidal Injection | IVT: Intravitreal Injection | PK: Pharmacokinetic | LLOQ: lower limit of quantification, 0.15 mg/mL | RPE: Retinal pigment epithelium

Concentration (nM)

CLS-AX Phase 1/2a Clinical Trial in Wet AMD

Trial Design

- Open-label study to assess the safety and tolerability of single doses of CLS-AX administered through suprachoroidal injection
- 3 Cohorts of 5 patients each: n=15
- Dose-escalation will begin at 0.03 mg CLS-AX; proceed to next cohort following review by Safety Monitoring Committee




Key Inclusion Criteria

- Active subfoveal choroidal neovascularization secondary to AMD
- Two or more anti-VEGF treatments in the 4 months preceding the screening visit with a meaningful response
- BCVA score of ≥ 20 letters (20/400) and ≤ 75 letters (20/32) with < 5 letters change between screening and baseline to ensure
 patient stability after anti-VEGF



CLS-AX Phase 1/2a Study Objectives

Primary Endpoint Evaluate safety and tolerability over 3 months of a single dose of CLS-AX given via suprachoroidal injection following IVT aflibercept





Early Stage Pipeline Opportunities



Broad Applicability of SCS Injection Platform: Ocular Gene Therapy

Primary Need Targeted delivery of ocular gene therapies in safe, effective, repeatable, and non-surgical manner

The Opportunity

- Avoid risks of vitrectomy (surgery)
- Avoid risks of retinotomy, subretinal injection, and macular detachment
- Deliver larger genes using non-viral vectors
- Convert gene therapy into an office-based procedure
- Potential for broader retinal coverage
- Enhance patient access



Preclinical Studies Demonstrate Suprachoroidal Injections of DNA nanoparticles (DNPs) May Offer the Potential for a Safe and Efficient Delivery Method

Potential Advantages

Efficacy: demonstrated in numerous ocular animal models

• Transfer large genes (up to ~20 kb)

Safety: Non-immunogenic, without viral capsid proteins or pre-existing immunity.

- Potential for repeat dosing facilitated by suprachoroidal injection
- Higher doses possible to enhance transfection


Well established literature on DNA nanoparticle gene therapy


	ternational Journal of Nanomedicine	opena come to acimulific and meetical ensearch
8	Suen-Access Full Yant Article	ORIGINAL RESEARCH
	NA nanoparticles are safe an on-human primate eyes	nd nontoxic in
MEN 8 M	CCIISS Preety evaluable online	@ PLOS •
D epertmen	ao Han ¹ , Shannon M. Conley ¹ , Rasha Makkia ¹ , J t d Cel Biology, University of Okishoma Hwith Sciences Center, Okishoma Ng, United States of America 	
Gene	The documents or Biometricon Considering O 2003 by The American Society for Biochemistry and Malecular Biology, Inc.	Vol. 275, No. 35, Inexas of August 22, pp. 335778-325565, 20 Printed in U.S.
Gene	The Average of Research Congress O 2001 by The American Notaty for Historisity and Milecular History, Inc. Nanoparticles of Compacted DNA	
Gene curre as co	Nanoparticles of Compacted DNA	
Gene curre as co	Nanoparticles of Compacted DNA Published	Transfect Postmitotic Cells* Received for publication, June 2, 200 , JBC Papers in Press, June 14, 2003, DOI 10.1074/jbc.M30577621 avy1, Tomasz H. Kowalczyk1, Christopher R. Gedeon1, mothy J. Miller1, Peter Brunovakis1,
Gene curre as co	Nanoparticles of Compacted DNA Published Ge Liutž, DeShan Lit, Murali K. Pasumarti Susannah L. Hyatti, Jennifer M. Payner, T Tamara L. Finkt, Osman Muhammady, Rol and Mark J. Coopert ^a	Transfect Postmitotic Cells* Received for publication, June 2, 200 , JBC Papers in Press, June 14, 2003, DOI 10.1074/jbc.M30677762 ay %, Tomasz H. Kowalczyk %, Christopher R. Gedeon%, mothy J. Miller %, Peter Brunovskis%, ert C. Moent, Richard W. Hanson5, Reserve University School of Medicine, Cleveland, Ohio 44106



The Suprachoroidal Space Reversibly Opens Posteriorly and Circumferentially Following DNA Nanoparticle Administration in Rabbits

[Day 1] The suprachoroidal space (SCS) opens posteriorly to the optic nerve head (ONH) after DNA nanoparticle administration.






[Day 30] There is well-tolerated reversible closure of the SCS after DNA nanoparticle administration.

Preclinical Suprachoroidal and Subretinal Injections of DNA Nanoparticles Produced Comparable Luciferase Activity

CHOROID-RPE-Sclera Non-Viral Luciferase, Rabbit RETINA Non-Viral Luciferase, Rabbit





DNA Nanoparticles Transfect Choroid and Retina



Published Preclinical Data on Viral Vectors in SCS

Suprachoroidal delivery of NAV AAV8-based gene therapy produced similar protein expression and suppression of vascular leakage







Broad Applicability of SCS Injection Platform: Integrin Inhibitor

Primary Need Targeted delivery addressing disease-modifying pathways beyond anti-VEGF therapy


The Opportunity

- Novel target
- Early industry validation in DME and AMD
- Advantages of targeted suprachoroidal administration with potential for:
 - Extended durability
 - Improved safety profile, through compartmentalization in SCS
 - Enhanced efficacy, through drug levels at affected tissues
- Limited potential competition



Integrin Inhibitors

- Multi-functional cell-adhesion molecules, heterodimeric receptors with α and β subunits
 - Connect extracellular matrix (ECM) to actin cytoskeleton in the cell cortex
 - Regulate cellular adhesion, migration, proliferation, invasion, survival, and apoptosis
 - Also play a role in inflammation, angiogenesis and fibrosis
- Integrins $\alpha_{_{V}}\beta_{_{3}}$ and $\alpha_{_{V}}\beta_{_{5}}$ implicated in DR and AMD
 - Given unique MOA, could serve as:
 - Primary therapy
 - Adjunctive therapy to anti-VEGF
 - Secondary therapy in refractory cases
- Clearside anti-integrin therapy
 - Formulated as a suprachoroidal suspension with extended duration potential
 - Initiating preclinical studies





Corporate Collaborations



Four Partnering Deals to Drive Growth







Validates our investment in suprachoroidal delivery using our **SCS** Microinjector



Maximizes the commercial and development opportunities for XIPERE in multiple geographic markets

Expands our overall internal and collaborative product development pipeline

Eligible to receive >\$230M from the four partnerships in potential development and sales milestones, and potential royalties to fund our internal R&D pipeline





Enabling In-office Delivery of Gene Therapy for Retinal Disease

The Opportunity: Gene Therapy

- Exclusive worldwide rights to our SCS Microinjector for delivery of adeno-associated virus (AAV)-based therapeutics to the suprachoroidal space to treat wet AMD, diabetic retinopathy and other conditions for which anti-VEGF treatment is the standard of care
- Delivery of gene therapy through the SCS may provide a targeted, in-office, non-surgical treatment approach option
- Encouraging preclinical results delivering RGX-314 into the SCS



The Terms:

- \$2M upfront / exercise of option
- Up to \$34M in development milestones across multiple indications
- Up to \$102M in sales milestones
- Mid single digit royalties on net sales of products using SCS Microinjector



REGENXBIO Initiating Two Phase 2 Trials Using SCS Microinjector®

- RGX-314 for Treatment of Wet Age-Related Macular Degeneration (wet AMD)
 - REGENXBIO Phase 2 AAVIATE trial of suprachoroidal delivery of RGX-314 using SCS Microinjector[™] for treatment of wet AMD <u>is active</u>. Enrollment expected to begin in <u>Q3 2020</u>.
 - AAVIATE is a multi-center, open-label, randomized, active-controlled, dose-escalation study that will evaluate the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314. N=40 patients with severe wet AMD who are responsive to anti-VEGF treatment.
 - Interim data is expected from Cohort 1 by the <u>end of 2020</u>.
- RGX-314 for Treatment of Diabetic Retinopathy (DR)
 - REGENXBIO plans to initiate Phase 2 trial of suprachoroidal delivery of RGX-314 using SCS Microinjector for treatment of DR in <u>second half of 2020</u> with interim data expected <u>in 2021</u>.





Optimizing Ocular Oncology Drug Delivery with SCS Microinjector™

The Opportunity: Ocular Oncology

- Worldwide licensing agreement for the use of our SCS Microinjector to deliver their proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma
- Non-surgical alternative to intravitreal delivery of Aura's oncology drug candidates via our SCS Microinjector
- Choroidal melanoma is the most common, primary intraocular tumor in adults
- Expect Aura to initiate clinical testing using our SCS Microinjector in the <u>third quarter of 2020</u>



The Terms:

- Potential future financial upside for Clearside from pre-specified development and sales milestones
- Royalties on net sales of products using SCS Microinjector



Novel Approach to Targeting Uveitic Macular Edema Using SCS Microinjector[®]

(triamcinolone acetonide suprachoroidal injectable suspension) 40 mg/mL

- Macular edema is the leading cause of vision loss in patients with non-infectious uveitis
- Pivotal Phase 3 PEACHTREE trial met its primary endpoint
- MAGNOLIA Phase 3 extension study demonstrated durability
- If approved, XIPERE would be the first therapy for this indication
- Expect to resubmit NDA with three months additional stability data in 1H, 2021



Maximizing Commercial Potential of XIPERE™

The Opportunity: XIPERE Commercialization & Development

- Exclusive license for XIPERE commercialization and development in the U.S. and Canada
- Exclusive options for (i) Europe and the United Kingdom, (ii) Australia and New Zealand, (iii) South America & Mexico
- Right to develop and commercialize XIPERE for additional ophthalmic indications including diabetic macular edema and retinal vein occlusion
- Right to develop and commercialize a specified set of corticosteroids and non-steroidal anti-inflammatory drugs in ophthalmology using our proprietary SCS Microinjector

• Received \$5M upfront payment

The Terms:

- Up to \$15M in FDA approval and pre-launch milestones
- Up to \$57.3M in milestone payments
- Tiered royalties at increasing percentages from the high-teens to 20% on annual net sales

BAUSCH-Health



Maximizing Commercial Potential of XIPERE™

The Opportunity: XIPERE Commercialization & Development in Greater China and South Korea

- Exclusive license to develop and commercialize XIPERE for indications associated with uveitis in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea
- Right to develop and commercialize XIPERE for additional ophthalmic indications in Greater China and South Korea, with consent from Clearside

The Terms:

- Received \$4M upfront payment
- Up to \$31.5M in approval, development and sales milestones
- Tiered royalties of 10% to 12% based on annual net sales starting at product launch and going until the later of ten years after launch or loss of patent protection or marketing exclusivity in the territory





Research and Development Investment Highlights

Versatile therapeutic platform with proprietary access to the suprachoroidal space

Patented technology & delivery approach

Scientific presentations and publications

- ✓ 1Q 20
 - Ophthalmology
 - Angiogenesis
 - Macula Society

✓ 2Q 20: ARVO

3Q 20: ASRS & Retina Society **4Q 20:** AAO Building an internal R&D pipeline

Mid 2020: IND
 Submission for CLS-AX

YE 20: Initiate Phase 1/2a Trial for CLS-AX

2H 20: Initiate Integrin Inhibitor Preclinical Studies

Exploratory preclinical SC non-viral vector delivery studies ongoing

Partnering to expand use of SCS platform

REGENXBIO: RGX-314*

✓ 3Q 20: Initiate Phase 2
 AAVIATE Trial in wet AMD


YE 20: AAVIATE Cohort 1 Data

2H 20: Initiate Phase 2 in DR

AURA: AU-011^

3Q 20: Initiate Phase 2 Clinical Testing in Choroidal Melanoma







Nasdaq: CLSD